TSPO and Brain atrophy: To evaluate the effect of TSPO ligand Ro5 treatment on brain atrophy, cortical, hippocampal, and cerebellar volumes were measured longitudinally in vivo by volumetric MRI at baseline (5 months) and following treatment (9 months; Fig. 1a).